| Revenue growth | H2 FY26 revenue grew 41% YoY to ₹80.1cr. |
|---|---|
| Margins | Gross margins dipped to 39% due to RM cost/mix changes. |
| Demand visibility | Strong demand in nutraceuticals and pet care segments. |
| Management confidence | Highly optimistic, emphasizing strategic hiring and capacity expansion for FY27. |
Growth
FY26 revenue hit ₹146cr; nutraceuticals grew 40% while Ayurvedic products surged 89% YoY.
Outlook
Targeting ₹450-500cr revenue by FY29; new facility operational by Aug 2026 increasing capacity 2.5x.
Risks
High client concentration with top 10 clients contributing 49% of revenue; margin compression due to front-loaded employee costs.
Earnings Call filed with NSE, NSE: INFLUX. Summary written with AI assistance from the document.
Influx Healthtech Ltd: key numbers
- Share price
- ₹281.45
- Market cap
- ₹651.6 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 31.7×Sector 50.4×
- Promoter holding
- 73.53%
- FII holding
- 0.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Influx Healthtech Ltd
All →Influx Healthtech Legal & Regulatory
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
- Value
- ₹0.02 Cr
Influx Healthtech Annual General Meeting
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech Other Announcement
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech reported FY26 revenue of ₹146cr, a 41% YoY increase, with PAT at ₹20.5cr. Strategy focuses on scaling nutraceutical CDMO capacity by 2.5x through a new 75,000 sq ft facility.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong FY26 performance as a specialist CDMO in nutraceuticals and cosmetics, focusing on capacity expansion and new technology implementation following its 2025 NSE listing.
Influx Healthtech H2 FY26 Results: Net Profit ₹10.5 Cr, Up 36.4% YoY
Influx Healthtech Ltd reported revenue from operations of ₹80.1 Cr (+41.0% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for H2 FY26.
- Key figure
- Net profit ₹10.5 Cr · +36.4% YoY